Focal Treatments for Prostate Cancer
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical necessity determinations for focal ablative treatments (e.g., focal laser, HIFU, cryoablation, RFA, photodynamic therapy, irreversible electroporation) for localized prostate cancer for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Coverage stances
from policy statement
from policy statement
Evidence summary and coverage implication
Coverage stance based on evidence:
Supports noncoverage determination for focal therapies as a class in this policy window.
For Medicare Advantage Plans, the policy states that use of any focal therapy modality to treat patients with localized prostate cancer is not covered because the evidence is insufficient to determine the effects of these technologies on health outcomes. For Commercial Products, the policy indicates that use of any focal therapy modality to treat patients with localized prostate cancer is not medically necessary for the same reason — insufficient evidence regarding effects on health outcomes.
The policy lists specific CPT/CPT®-like codes that are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products. These include: 0655T (transperineal focal laser ablation of malignant prostate tissue), 0739T (ablation by magnetic field induction with nanoparticle activation), and 55880 (transrectal HIFU ablation of malignant prostate tissue). The policy also notes that when services lack an assigned CPT code, 55899 (unlisted procedure, male genital system) should be used.
For Commercial Products, focal therapy modalities for localized prostate cancer are considered not medically necessary because the available evidence is heterogeneous, lacks prospective comparative trials for most focal techniques versus standard treatments, has short follow-up and small sample sizes, and methods for selecting and treating lesions are not standardized. Given these limitations, the evidence is insufficient to determine improvement in net health outcome, supporting the not medically necessary determination.
The policy explicitly states that the following procedure codes are not medically necessary for Commercial Products: 0655T, 0739T, and 55880. These codes describe transperineal focal laser ablation, magnetic field–induction ablation with nanoparticle activation, and transrectal HIFU ablation, respectively. When an appropriate CPT is not available, use 55899 (unlisted procedure, male genital system).
The evidence assessing focal therapies (laser ablation, HIFU, cryoablation, RFA, photodynamic therapy, irreversible electroporation) is highly heterogeneous and inconsistently reports clinical outcomes. There are no prospective, comparative trials for most focal techniques versus standard treatments, methods for selecting lesions to treat are not standardized, and studies have short follow-up and small sample sizes. Consequently, the evidence is insufficient to determine that these therapies improve net health outcome, and the therapies are treated as not supported by sufficient evidence in this policy.
Coding
| No codes listed |
| 0655T | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging |
| 0739T | Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation |
| 55880 | Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance |
| 55899 | Unlisted procedure, male genital system |
Provider Actions & Billing Guidance
Prior authorization not applicable
Prior authorization is not applicable for focal therapies in this policy.
Billing and code requirements
The policy lists specific CPT codes as not covered or directs use of an unlisted procedure code when no CPT exists; follow payer billing rules and member-specific authorization processes per benefits and participation agreements.
No medical criteria specified
No medical criteria or step therapy requirements are specified in this draft policy.
No step therapy requirements
This document does not establish any step therapy requirements for focal therapies.
Refer to applicable Benefit Booklet/Evidence of Coverage
Benefits and coverage can vary by contract; refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for group-specific coverage details.
Use unlisted code 55899 when no CPT assigned
If a service addressed by this policy lacks an assigned CPT code, bill using Unlisted procedure code 55899 (Unlisted procedure, male genital system).
Claims for focal therapy will be denied/not covered
Claims for any focal therapy modality to treat localized prostate cancer will be denied or are not covered under the policy statements for Medicare Advantage and Commercial Products.
- Medicare Advantage: focal therapies are not covered (insufficient evidence).
- Commercial Products: focal therapies are not medically necessary (insufficient evidence).
Background
Localized prostate cancer is common and can have variable behavior, making treatment selection challenging. Radical whole-gland treatments (for example, radical prostatectomy or external-beam radiotherapy) can provide disease control but are associated with substantial adverse effects on urinary, sexual, and rectal function. Focal therapy aims to ablate the index lesion or other cancerous lesions using targeted energy-based methods (such as laser, HIFU, cryoablation, RFA, photodynamic therapy, or irreversible electroporation) to reduce tumor burden while attempting to preserve urinary, erectile, and rectal function. However, available evidence is limited and does not currently demonstrate consistent improvement in long-term clinical outcomes compared with standard treatments.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.